Chinese Pharma Recovers Most Of Contaminated Human Rabies Vaccine
This article was originally published in PharmAsia News
Executive SummaryChina's Dalian Jingang-Andi Bio-products says it has recovered nearly all of the 360,200 doses of its human rabies vaccine, 20 percent of the Chinese market, found to be contaminated. The company produced the vaccine last year, but tests in January by the General Administration of Quality Supervision, Inspection and Quarantine, found an illegal nucleic acid adjuvant. The agency had announced earlier that nucleic acid materials could not be used in human vaccines until they undergo clinical trials. No deaths from the vaccine have been reported, a company spokeswoman said. (Click here for more
You may also be interested in...
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced January 2020.
Industry experts expect a continued uptick in deals valued between $2bn-$10bn this year as buyers look to add critical mass in areas like oncology, rare disease and cell and gene therapy. Divestitures to free up capital and narrow focus should continue too.
UK-centric investment firm Syncona’s model of “founding, building and funding” early-stage biotech companies – with a commitment to the longer term – hopes to help make Great Britain a cell and gene therapy powerhouse.